All In Biotech

Drug Trial Radar · NCT07742098

A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke

A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Domain Within the ACT-GLOBAL Trial Platform, to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Oct 31, 2026

Primary completion

Dec 15, 2028

Study completion Dec 15, 2028

Sponsor

Lead sponsor
NeuroTrauma Sciences, LLCIndustry
Sponsor type
Industry
First posted
Aug 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 45 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.

Conditions

  • Acute Ischemic Stroke

Interventions

  • NTS-521Drug

    Intravenous NTS-521

  • Placebo ControlOther

    0.9% saline solution delivered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety AssessmentTime frame: Safety assessments between baseline and Day 30 and Day 90

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.